Rigontec starts FIH Phase I/II trial of RIG-I agonist RGT100 & appoints new CMO3. May 2017|In Portfolio News|By eazee-designstudioRigontec today announced the dosing of the first patient in a phase I/II study with intratumoral/intralesional administration of its lead compound RGT100 in solid tumors and lymphoma. In addition, Rigontec appoints industry veteran Prof. Eugen Leo as Chief Medical Officer. PrevNext
